Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in ALK+ NSCLC
NCT04318938Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Mar 2020
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brigatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Progression-Free Survival of 1st-line treatment at 68 months. Started Mar 2020; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04318938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318938.